Table 2.
Omega-3 intake and the development of incident liver disease and hepatocellular carcinoma in individuals without prior liver disease in UKB.
| Omega-3 intake | No Omega-3 intake | ||||
|---|---|---|---|---|---|
| No. with event/ total No. | Hazard ratio (95% CI) | No. with event/ total No. | Hazard ratio (95% CI) | p-value | |
| Incident Liver disease* | 350/38,121 | 0.716 (0.639 to 0.802) | 4,010/373,035 | 1.00 (reference) | 7.6e-09 |
| Alcoholic liver disease (K70) | 27/38,121 | 0.559 (0.347 to 0.833) | 404/373,035 | 1.00 (reference) | 4.3e-03 |
| Toxic liver disease (K71) | 5/38,121 | 0.96 (0.36 to 2.58) | 34/373,035 | 1.00 (reference) | 0.94 |
| Hepatic failure, not elsewhere classified (K72) | 20/38,121 | 0.548 (0.343 to 0.875) | 270/373,035 | 1.00 (reference) | 1.2e-02 |
| Chronic hepatitis, not elsewhere classified (K73) | 7/38,121 | 1.42 (0.61 to 3.30) | 51/373,035 | 1.00 (reference) | 0.42 |
| Fibrosis and cirrhosis of liver (K74) | 52/38,121 | 0.76 (0.57 to 1.02) | 558/373,035 | 1.00 (reference) | 0.07 |
| Other inflammatory liver diseases (K75) | 61/38,121 | 1.02 (0.77 to 1.34) | 508/373,035 | 1.00 (reference) | 0.90 |
| Other diseases of liver (K76) | 253/38,121 | 0.711 (0.623 to 0.812) | 3,034/373,035 | 1.00 (reference) | 5.1e-07 |
| Fatty (change of) liver, not elsewhere classified (K76.0) | 128/38,121 | 0.784 (0.650 to 0.944) | 1,533/373,035 | 1.00 (reference) | 1.0e-02 |
| MRI confirmed steatosis (>5% liver fat) | 832/38,121** | 0.846 (0.777 to 0.921) | 7,546/373,035*** | 1.00 (reference) | 1.1e-04 |
| Liver disorders in diseases classified elsewhere (K77) | <5/38,121 | 2.00 (0.38 to 10.51) | 8/373,035 | 1.00 (reference) | 0.42 |
| Liver cell carcinoma (C220) | 9/38,121 | 0.66 (0.32 to 1.33) | 108/373,035 | 1.00 (reference) | 0.24 |
*Incident Liver Disease is defined as new onset Liver Disease K70-K77 after Baseline examination. **34,905 missing values and ***345,035 missing values. Bold values are significant (p-value < 0.05).